{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-016017","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.448171+00:00","generated_at":"2026-05-16T09:36:16.692352+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027","bullets":["Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.","Company expects topline data readout from ALSTARS Phase 2 trial in first quarter of 2027.","Updates conveyed in letter to stockholders dated January 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-016017","json":"https://secwatch.observer/filing/0001193125-26-016017.json","markdown":"https://secwatch.observer/filing/0001193125-26-016017.md","text":"https://secwatch.observer/filing/0001193125-26-016017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/0001193125-26-016017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/d48170d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:36:16.692352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}